230 related articles for article (PubMed ID: 33452453)
1. Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells.
Lin S; Zhang X; Huang G; Cheng L; Lv J; Zheng D; Lin S; Wang S; Wu Q; Long Y; Li B; Wei W; Liu P; Pei D; Li Y; Wen Z; Cui S; Li P; Sun X; Wu Y; Yao Y
Oncogene; 2021 Feb; 40(8):1476-1489. PubMed ID: 33452453
[TBL] [Abstract][Full Text] [Related]
2. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylethanolamine-binding protein 4 promotes the epithelial-to-mesenchymal transition in non-small cell lung cancer cells by activating the sonic hedgehog signaling pathway.
Jian W; Bai Y; Li X; Kang J; Lei Y; Xue Y
J Cell Biochem; 2019 Apr; 120(4):5386-5395. PubMed ID: 30367510
[TBL] [Abstract][Full Text] [Related]
5. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
[TBL] [Abstract][Full Text] [Related]
6. ERas regulates cell proliferation and epithelial-mesenchymal transition by affecting Erk/Akt signaling pathway in pancreatic cancer.
Liu Y; Qin P; Wu R; Du L; Li F
Hum Cell; 2020 Oct; 33(4):1186-1196. PubMed ID: 32700262
[TBL] [Abstract][Full Text] [Related]
7. The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p.
Wei S; Zheng Y; Jiang Y; Li X; Geng J; Shen Y; Li Q; Wang X; Zhao C; Chen Y; Qian Z; Zhou J; Li W
EBioMedicine; 2019 Jun; 44():182-193. PubMed ID: 31160270
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
9. miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells.
Tang H; Lv W; Sun W; Bi Q; Hao Y
Int J Mol Med; 2019 Mar; 43(3):1203-1216. PubMed ID: 30628663
[TBL] [Abstract][Full Text] [Related]
10. FMNL1 down-regulation suppresses bone metastasis through reducing TGF-β1 expression in non-small cell lung cancer (NSCLC).
Yang XY; Liao JJ; Xue WR
Biomed Pharmacother; 2019 Sep; 117():109126. PubMed ID: 31387165
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer.
Wang L; Tong X; Zhou Z; Wang S; Lei Z; Zhang T; Liu Z; Zeng Y; Li C; Zhao J; Su Z; Zhang C; Liu X; Xu G; Zhang HT
Mol Cancer; 2018 Sep; 17(1):140. PubMed ID: 30261900
[TBL] [Abstract][Full Text] [Related]
12. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
13. PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer.
Wu DM; Deng SH; Zhou J; Han R; Liu T; Zhang T; Li J; Chen JP; Xu Y
Int J Cancer; 2020 May; 146(9):2563-2575. PubMed ID: 31498891
[TBL] [Abstract][Full Text] [Related]
14. EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in non‑small cell lung cancer cells.
Gao L; Yang T; Zhang S; Liang Y; Shi P; Ren H; Hou P; Chen M
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907840
[TBL] [Abstract][Full Text] [Related]
15. SRPX2 promotes cell proliferation and invasion via activating FAK/SRC/ERK pathway in non-small cell lung cancer.
Li X; Liu J; Sun H; Zou Y; Chen J; Chen Y; Chen C; Wu X
Acta Biochim Pol; 2020 Jun; 67(2):165-172. PubMed ID: 32550700
[TBL] [Abstract][Full Text] [Related]
16. SPARC acts as a mediator of TGF-β1 in promoting epithelial-to-mesenchymal transition in A549 and H1299 lung cancer cells.
Sun W; Feng J; Yi Q; Xu X; Chen Y; Tang L
Biofactors; 2018 Sep; 44(5):453-464. PubMed ID: 30346081
[TBL] [Abstract][Full Text] [Related]
17. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
Liu X; Sun L; Zhang S; Zhang S; Li W
J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
[TBL] [Abstract][Full Text] [Related]
18. MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer.
Liu MX; Zhou KC; Cao Y
Mol Cancer; 2014 Nov; 13():245. PubMed ID: 25373388
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt/β-catenin signaling in non-small-cell lung cancer.
Yang Y; Sun Y; Wu Y; Tang D; Ding X; Xu W; Su B; Gao W
Mol Carcinog; 2018 Jul; 57(7):842-853. PubMed ID: 29566281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
